skip to content
Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary Preview this item
ClosePreview this item
Checking...

Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary

Author: Denise Caruso; Rebecca A English; Anne B Claiborne; Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation,
Publisher: Washington, D.C. : National Academies Press, [2014]
Edition/Format:   eBook : Document : Conference publication : EnglishView all editions and formats
Summary:
Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limitations in the research and clinical trial process itself that might limit the generalizability of results. As a result, regulatory reviewers are consistently required to  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Congress
Electronic books
Conference papers and proceedings
Congresses
Additional Physical Format: Print version:
Caruso, Denise.
Characterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products : workshop summary.
Washington, District of Columbia : The National Academies Press, ©2014
xvi, 134 pages
Material Type: Conference publication, Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Denise Caruso; Rebecca A English; Anne B Claiborne; Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation,
ISBN: 9780309310000 0309310008 9780309310017 0309310016
OCLC Number: 904080937
Notes: Title from PDF title page.
Description: 1 online resource (1 PDF file (xvi, 134 pages)) : illustrations
Contents: Introduction --
Identifying and characterizing uncertainty --
The regulators' challenge --
Basic methodologies and applications for understanding and evaluating uncertainty --
Communicating uncertainty --
Final reflections on ways to characterize and communicate uncertainty.
Responsibility: Denise Caruso, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Abstract:

Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limitations in the research and clinical trial process itself that might limit the generalizability of results. As a result, regulatory reviewers are consistently required to draw conclusions about a drug's safety and efficacy from imperfect data. Efforts are underway within the drug development community to enhance the evaluation and communication of the benefits and risks associated with pharmaceutical products, aimed at increasing the predictability, transparency, and efficiency of pharmaceutical regulatory decision making. Effectively communicating regulatory decisions necessarily includes explanation of the impact of uncertainty on decision making. On February 12 and May 12, 2014, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held public workshops to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in the assessment of benefits and risks, and to consider their implications for pharmaceutical regulatory decisions. Workshop presentations and discussions on February 12 were convened to explore the science of identifying and characterizing uncertainty in scientific evidence and approaches to translate uncertainties into decisions that reflect the values of stakeholders. The May 12 workshop presentations and discussions explored tools and approaches to communicating about scientific uncertainties to a range of stakeholders in the drug development process. Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products summarizes the presentation and discussion of both events. This report explores potential analytical and communication approaches and identifies key considerations on their development, evaluation, and incorporation into pharmaceutical benefit-risk assessment throughout the entire drug development lifecycle.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/904080937> # Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "904080937" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/dcu> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/social_science_general> ; # SOCIAL SCIENCE--General
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_government_policy> ; # Drugs--Testing--Government policy
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_government_policy_united_states> ; # Drugs--Testing--Government policy--United States
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_law_and_legislation_united_states> ; # Drugs--Testing--Law and legislation--United States
    schema:about <http://dewey.info/class/363.1/e23/> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/pharmaceutical_preparations> ; # Pharmaceutical Preparations
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/communication> ; # Communication
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_risk_assessment_united_states_decision_making> ; # Drugs--Risk assessment--United States--Decision making
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/business_&_economics_infrastructure> ; # BUSINESS & ECONOMICS--Infrastructure
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/risk_assessment> ; # Risk Assessment
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_law_and_legislation_united_states_decision_making> ; # Drugs--Law and legislation--United States--Decision making
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drug_industry_standards> ; # Drug Industry--standards
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/legislation_drug> ; # Legislation, Drug
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/pharmaceutical_policy_united_states_decision_making> ; # Pharmaceutical policy--United States--Decision making
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_law_and_legislation> ; # Drugs--Testing--Law and legislation
    schema:about <http://experiment.worldcat.org/entity/work/data/2409782379#Place/united_states> ; # United States.
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2409782379#Person/claiborne_anne_b> ; # Anne B. Claiborne
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2409782379#Person/english_rebecca_a> ; # Rebecca A. English
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2409782379#Organization/institute_of_medicine_u_s_forum_on_drug_discovery_development_and_translation> ; # Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation,
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2409782379#Meeting/characterizing_and_communicating_uncertainty_in_the_assessment_of_benefits_and_risks_of_pharmaceutical_products_workshop_2014_white_oak_md> ; # Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products (Workshop) (2014 : White Oak, Md.)
    schema:creator <http://experiment.worldcat.org/entity/work/data/2409782379#Person/caruso_denise_1956> ; # Denise Caruso
    schema:datePublished "2014" ;
    schema:description "Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limitations in the research and clinical trial process itself that might limit the generalizability of results. As a result, regulatory reviewers are consistently required to draw conclusions about a drug's safety and efficacy from imperfect data. Efforts are underway within the drug development community to enhance the evaluation and communication of the benefits and risks associated with pharmaceutical products, aimed at increasing the predictability, transparency, and efficiency of pharmaceutical regulatory decision making. Effectively communicating regulatory decisions necessarily includes explanation of the impact of uncertainty on decision making. On February 12 and May 12, 2014, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held public workshops to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in the assessment of benefits and risks, and to consider their implications for pharmaceutical regulatory decisions. Workshop presentations and discussions on February 12 were convened to explore the science of identifying and characterizing uncertainty in scientific evidence and approaches to translate uncertainties into decisions that reflect the values of stakeholders. The May 12 workshop presentations and discussions explored tools and approaches to communicating about scientific uncertainties to a range of stakeholders in the drug development process. Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products summarizes the presentation and discussion of both events. This report explores potential analytical and communication approaches and identifies key considerations on their development, evaluation, and incorporation into pharmaceutical benefit-risk assessment throughout the entire drug development lifecycle."@en ;
    schema:description "Introduction -- Identifying and characterizing uncertainty -- The regulators' challenge -- Basic methodologies and applications for understanding and evaluating uncertainty -- Communicating uncertainty -- Final reflections on ways to characterize and communicate uncertainty."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/2409782379> ;
    schema:genre "Conference papers and proceedings"@en ;
    schema:genre "Conference publication"@en ;
    schema:genre "Congress"@en ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isSimilarTo <http://worldcat.org/entity/work/data/2409782379#CreativeWork/characterizing_and_communicating_uncertainty_in_the_assessment_of_benefits_and_risks_of_pharmaceutical_products_workshop_summary> ;
    schema:name "Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary"@en ;
    schema:productID "904080937" ;
    schema:url <http://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9780309310031> ;
    schema:url <http://www.nap.edu/catalog/18870/characterizing-and-communicating-uncertainty-in-the-assessment-of-benefits-and-risks-of-pharmaceutical-products> ;
    schema:url <http://www.nap.edu/openbook.php?record_id=18870> ;
    schema:url <http://www.nap.edu/catalog.php?record_id=18870> ;
    schema:url <https://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=3379407> ;
    schema:url <http://site.ebrary.com/id/11003355> ;
    schema:url <https://www.nap.edu/18870> ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK246889/> ;
    schema:url <http://VH7QX3XE2P.search.serialssolutions.com/?V=1.0&L=VH7QX3XE2P&S=JCs&C=TC0001467018&T=marc&tab=BOOKS> ;
    schema:url <https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=941878> ;
    schema:url <https://www.nap.edu/catalog.php?record_id=18870> ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK246889> ;
    schema:workExample <http://worldcat.org/isbn/9780309310017> ;
    schema:workExample <http://worldcat.org/isbn/9780309310000> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/904080937> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2409782379#Meeting/characterizing_and_communicating_uncertainty_in_the_assessment_of_benefits_and_risks_of_pharmaceutical_products_workshop_2014_white_oak_md> # Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products (Workshop) (2014 : White Oak, Md.)
    a bgn:Meeting, schema:Event ;
    schema:location <http://experiment.worldcat.org/entity/work/data/2409782379#Place/white_oak_md> ; # White Oak, Md.)
    schema:name "Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products (Workshop) (2014 : White Oak, Md.)" ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Organization/institute_of_medicine_u_s_forum_on_drug_discovery_development_and_translation> # Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation,
    a schema:Organization ;
    schema:name "Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation," ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Person/caruso_denise_1956> # Denise Caruso
    a schema:Person ;
    schema:birthDate "1956" ;
    schema:familyName "Caruso" ;
    schema:givenName "Denise" ;
    schema:name "Denise Caruso" ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Person/claiborne_anne_b> # Anne B. Claiborne
    a schema:Person ;
    schema:familyName "Claiborne" ;
    schema:givenName "Anne B." ;
    schema:name "Anne B. Claiborne" ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Person/english_rebecca_a> # Rebecca A. English
    a schema:Person ;
    schema:familyName "English" ;
    schema:givenName "Rebecca A." ;
    schema:name "Rebecca A. English" ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Place/united_states> # United States.
    a schema:Place ;
    schema:name "United States." ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Place/white_oak_md> # White Oak, Md.)
    a schema:Place ;
    schema:name "White Oak, Md.)" ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/business_&_economics_infrastructure> # BUSINESS & ECONOMICS--Infrastructure
    a schema:Intangible ;
    schema:name "BUSINESS & ECONOMICS--Infrastructure"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drug_industry_standards> # Drug Industry--standards
    a schema:Intangible ;
    schema:name "Drug Industry--standards"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_law_and_legislation_united_states_decision_making> # Drugs--Law and legislation--United States--Decision making
    a schema:Intangible ;
    schema:name "Drugs--Law and legislation--United States--Decision making"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_risk_assessment_united_states_decision_making> # Drugs--Risk assessment--United States--Decision making
    a schema:Intangible ;
    schema:name "Drugs--Risk assessment--United States--Decision making"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_government_policy> # Drugs--Testing--Government policy
    a schema:Intangible ;
    schema:name "Drugs--Testing--Government policy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_government_policy_united_states> # Drugs--Testing--Government policy--United States
    a schema:Intangible ;
    schema:name "Drugs--Testing--Government policy--United States"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_law_and_legislation> # Drugs--Testing--Law and legislation
    a schema:Intangible ;
    schema:name "Drugs--Testing--Law and legislation"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/drugs_testing_law_and_legislation_united_states> # Drugs--Testing--Law and legislation--United States
    a schema:Intangible ;
    schema:name "Drugs--Testing--Law and legislation--United States"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/legislation_drug> # Legislation, Drug
    a schema:Intangible ;
    schema:name "Legislation, Drug"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/pharmaceutical_policy_united_states_decision_making> # Pharmaceutical policy--United States--Decision making
    a schema:Intangible ;
    schema:name "Pharmaceutical policy--United States--Decision making"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/pharmaceutical_preparations> # Pharmaceutical Preparations
    a schema:Intangible ;
    schema:name "Pharmaceutical Preparations"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2409782379#Topic/social_science_general> # SOCIAL SCIENCE--General
    a schema:Intangible ;
    schema:name "SOCIAL SCIENCE--General"@en ;
    .

<http://worldcat.org/entity/work/data/2409782379#CreativeWork/characterizing_and_communicating_uncertainty_in_the_assessment_of_benefits_and_risks_of_pharmaceutical_products_workshop_summary>
    a schema:CreativeWork ;
    rdfs:label "Characterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products : workshop summary." ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/904080937> ; # Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary
    .

<http://worldcat.org/isbn/9780309310000>
    a schema:ProductModel ;
    schema:isbn "0309310008" ;
    schema:isbn "9780309310000" ;
    .

<http://worldcat.org/isbn/9780309310017>
    a schema:ProductModel ;
    schema:isbn "0309310016" ;
    schema:isbn "9780309310017" ;
    .

<http://www.worldcat.org/title/-/oclc/904080937>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/904080937> ; # Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary
    schema:dateModified "2020-01-30" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.